Amphastar Asks Jury To Nix $1B Momenta Infringement Case
Amphastar Pharmaceuticals on Thursday told a federal jury in Boston that generic competitor Momenta's "outrageous" dishonesty in developing standards for a lucrative blood thinner should end the company's patent infringement case....To view the full article, register now.
Already a subscriber? Click here to view full article